Serum Interleukin-6 Levels Correlate with the Efficacy of Antiangiogenic Therapy in Metastatic Colorectal Cancer

Chen Y, Cai H, Liu Y, Zhang Q and Jia HJ

Department of Surgery, Chongqing Medical University, China

^*Correspondance to: Hou Jun Jia 

 PDF  Full Text Research Article | Open Access

Abstract:

Background: Identifying predictive indicators before starting treatment can enhance treatment accuracy. This study aims to assess the correlation between IL-6 concentration in the blood and the efficacy of antiangiogenic therapy for liver metastases from colorectal cancer. Methods: In this retrospective study, we examined 53 patients with CRLM who received nonsurgical treatment from June 2017 to June 2023. We collected serum IL-6 levels before starting treatment and evaluated their impact based on consensus guidelines. The ROC curve was used to determine the best cut-off point for IL-6. We compared treatment response rates using chi-square tests and estimated Overall Survival (OS) and Progression-Free Survival (PFS) using Kaplan-Meier and multivariate Cox proportional hazard regression analyses. Results: Out of the total of 53 patients, the median age was 64 years with a standard deviation of 10.2 years. Among them, 24 patients did not receive bevacizumab while the remaining 29 patients received a therapy that included bevacizumab. It was observed that patients who were treated with bevacizumab had a longer Progression-Free Survival (PFS) compared to those who did not receive it (P=0.04). Out of the 24 patients who received chemotherapy alone, 12 had a shorter PFS compared to the remaining 12 who had lower IL-6 levels (P=0.03). Similar differences were not observed in 29 patients receiving bevacizumab combination therapy (P=0.76). Conclusion: Patients with higher levels of IL-6 benefited from antiangiogenic therapy, whereas those with lower levels did not receive the same benefits from bevacizumab.

Keywords:

Colorectal cancer; Bevacizumab; Inflammation; Interleukin-6 (IL-6)

Cite the Article:

Chen Y, Cai H, Liu Y, Zhang Q, Jia HJ. Serum Interleukin-6 Levels Correlate with the Efficacy of Antiangiogenic Therapy in Metastatic Colorectal Cancer. Clin Oncol. 2023;8:2021..